Comparative Study between Once Daily LABA-LAMA (Indacaterolglycopyrronium) vs. Twice Daily LABA-LAMA (Formoterolglycopyrronium) in Stable COPD Patients Group B

Background: An inflammatory lung condition that lasts a long time is called chronic obstructive pulmonary disease (COPD), it results from exposure to noxious substances, abnormalities in the bronchi, and obstruction of lung airflow owing to alveoli. Objective: This study compares the safety and efficacy of LABA-LAMA combination therapy administered at varied frequencies to individuals with stable chronic obstructive pulmonary disease. The purpose of the study is to ascertain which of the two combinations performs better when considering both subjective and objective criteria. Methods: Patients with Group B Stable COPD in the outpatient department were assigned into two random groups of 50 and given a different medication combination. Those in Group 1 received a single daily dose of Indacaterol + Glycopyrrolate, while those in Group 2 received two daily doses of Formoterol + Glycopyrrolate. Every four weeks, patients were checked on individually. Spirometric data (FEV1 (% Pred), Trough FEV1 (L), FEV1/FVC), and symptoms (cough, shortness of breath, sputum production, sleep disturbance) were recorded for each patient. Results: After the therapy, both groups showed a decrease in symptomatic indicators. There was a notable improvement in trough FEV1 (L) and spirometric measurements. Moreover, no noticeable differences in subjective and objective criteria were observed between groups 1 and 2. Conclusion: This study's conclusions are limited to patient populations with comparable features. To further elucidate the risk factors and potential genetic foundation of the disease conditions, more multi-centric studies including diverse ethnic groups must be conducted.